Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Andrews

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Expert Review of Gastroenterology & Hepatology|July 12, 2024
Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) databaseMichael B Andrews, Douglas G Adler
Expert Opinion on Drug Safety|June 12, 2025
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, plecanatide, and Tenapanor: analysis of the FDA adverse event reporting system (FAERS) databaseMichael B Andrews, Douglas G Adler
Expert Opinion on Drug Safety|April 8, 2025
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) databaseMichael B Andrews, Douglas G Adler
Dalton Transactions (Cambridge, England : 2003)|December 14, 2011
Utilizing hydrogen bonds and halogen-halogen interactions in the design of uranyl hybrid materialsMichael B Andrews, Christopher L Cahill
ACG Case Reports Journal|April 11, 2025
Thyrotoxicosis-Induced Myopathic Dysphagia Treated With PlasmapheresisMichael B Andrews, Mary Stevenson, Puneet Puri
Expert Opinion on Drug Safety|April 12, 2025
Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implicationsPraneeth Kudaravalli, Michael B Andrews, Douglas G Adler
Future Science OA|May 15, 2026
A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implicationsCameron M Thompson, Michael B Andrews, Douglas G Adler
Case Reports in Gastrointestinal Medicine|June 23, 2025
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Initiation of Sulfasalazine for Ulcerative Colitis: A Yearlong Clinical ChallengeMichael B Andrews, Michael V Patrone, Stephen J Bickston
Endoscopic Ultrasound|May 19, 2025
Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System databaseCourtney N Walker, Michael B Andrews, Douglas G Adler
Inorganic Chemistry|December 17, 2013
Supramolecular interactions in PuO2Cl4(2-) and PuCl6(2-) complexes with protonated pyridines: synthesis, crystal structures, and Raman spectroscopyRichard E Wilson, David D Schnaars, Michael B Andrews, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Expert Review of Gastroenterology & Hepatology|July 12, 2024
Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) databaseMichael B Andrews, Douglas G Adler
Expert Opinion on Drug Safety|June 12, 2025
Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, plecanatide, and Tenapanor: analysis of the FDA adverse event reporting system (FAERS) databaseMichael B Andrews, Douglas G Adler
Expert Opinion on Drug Safety|April 8, 2025
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) databaseMichael B Andrews, Douglas G Adler
Dalton Transactions (Cambridge, England : 2003)|December 14, 2011
Utilizing hydrogen bonds and halogen-halogen interactions in the design of uranyl hybrid materialsMichael B Andrews, Christopher L Cahill
ACG Case Reports Journal|April 11, 2025
Thyrotoxicosis-Induced Myopathic Dysphagia Treated With PlasmapheresisMichael B Andrews, Mary Stevenson, Puneet Puri
Expert Opinion on Drug Safety|April 12, 2025
Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implicationsPraneeth Kudaravalli, Michael B Andrews, Douglas G Adler
Future Science OA|May 15, 2026
A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implicationsCameron M Thompson, Michael B Andrews, Douglas G Adler
Case Reports in Gastrointestinal Medicine|June 23, 2025
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Following Initiation of Sulfasalazine for Ulcerative Colitis: A Yearlong Clinical ChallengeMichael B Andrews, Michael V Patrone, Stephen J Bickston
Endoscopic Ultrasound|May 19, 2025
Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System databaseCourtney N Walker, Michael B Andrews, Douglas G Adler
Inorganic Chemistry|December 17, 2013
Supramolecular interactions in PuO2Cl4(2-) and PuCl6(2-) complexes with protonated pyridines: synthesis, crystal structures, and Raman spectroscopyRichard E Wilson, David D Schnaars, Michael B Andrews, et al.
Pageof 2